Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Xiaotian M. Zhang"'
Autor:
Cristina B. Guzman, Vincent Woo, S.J. Weisnagel, Xiaotian M. Zhang, Sheetal Pradhan, Gregg Gerety, George Tsoukas, Shuyu Zhang, Claude A. Piché, Elizabeth R. Seaquist, James R. Conway, Rémi Rabasa-Lhoret, Hélène Dulude, Dolorès Carballo
Publikováno v:
Diabetes, Obesity & Metabolism
In the present multicentre, open-label, prospective, phase III study, we evaluated the real-world effectiveness and ease of use of nasal glucagon (NG) in the treatment of moderate/severe hypoglycaemic events (HEs) in adults with type 1 diabetes (T1D)
Autor:
Parag Garhyan, Cristina B. Guzman, Thomas A. Hardy, Sudha S. Shankar, Rong Liu, Christof M. Kazda, Xiaotian M. Zhang, Sreekumar G. Pillai, Arie Regev, Naga Chalasani
Publikováno v:
Diabetes, Obesity and Metabolism. 19:1521-1528
AIMS To evaluate whether treatment with LY2409021, a novel, selective glucagon receptor antagonist, is associated with changes in hepatic fat and other safety variables related to the benefit-risk profile for chronic use in patients with type 2 diabe
Autor:
Cristina B, Guzman, Xiaotian M, Zhang, Rong, Liu, Arie, Regev, Sudha, Shankar, Parag, Garhyan, Sreekumar G, Pillai, Christof, Kazda, Naga, Chalasani, Thomas A, Hardy
Publikováno v:
Diabetes, obesitymetabolism. 19(11)
To evaluate whether treatment with LY2409021, a novel, selective glucagon receptor antagonist, is associated with changes in hepatic fat and other safety variables related to the benefit-risk profile for chronic use in patients with type 2 diabetes (